Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation

Figure 2

Sitagliptin improves NODAT control and is associated with a decline in BMI but no effect on serum lipids. (a) Diabetes control as measured by hemoglobin A1c for the entire cohort (𝑛=22) at 6 and 12 months after initiation of sitagliptin. (b) BMI for the entire cohort (𝑛=22) at start of sitagliptin compared to 12-month followup. (c), (d) Serum LDL-cholesterol and HDL-cholesterol at start of sitagliptin compared to 12-month followup. Data shown as mean + SD. ^∗∗𝑃<0.01, ^∗𝑃<0.05.

(a)

(b)

(c)

(d)